| Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the most effective treatment for a number of hematopoietic malignancies. However, graft-versus-host disease (GVHD) could not been totally avoid because of the difference of major histocompatibility complex. GVHD affects many organs including skin, liver and intestinal tract. Intestinal GVHD is particularly serious because of its frequency, severity and impact on the general condition of the patient. Serious intestinal GVHD is always cannot be cured, and it could amplify the systemic disease after Allo-HSCT. The lesion of intestinal mucosa is the major cause of intestinal GVHD which can also accelerate the aggravation of system GVHD via inducing the release of inflammatory cytokines. To cure intestinal GVHD, both repairing the damage of mucosa and modulating the immunity must be achieved.Hepatocyte growth factor (HGF) has mitogenic, motogenic and morphogenic effects on various tissues, particularly the intestine, kidneys and lungs. HGF has been applied in the tissue repair process. Mesenchymal stem cells (MSCs) are multipotential cells and have exhibited some special immunomodulatory abilities. We hypothesized that treatment with MSCs over-expressing HGF might be a novel strategy that can both repair the damage of the mucosa and suppress the immunological reaction, which could ultimately stop the process of GVHD. In this study, we transfected MSCs with plasmid pcDNA3.1-HGF and evaluated the expression of HGF by tresfected MSCs. By using a mouse intestinal acute GVHD model, we evaluated the preventive and therapeutic potential of MSCs over-expressing HGF, which is compared with using MSCs alone.Methods To investigate the therapeutic effect of MSCs over-expressing HGF, we established a mouse intestinal GVHD model by 5.5Gy TBI preparation regimen and mouse H-2 gene mismatched allogeneic hematopoietic stem cell transplantation. Bone marrow-derived MSCs were isolated, expanded, characterized, and transfected with... |
PDF Full Text Request